Hypercholesterolemia News and Research

RSS
Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. Cholesterol is a waxy, fat-like substance that is produced in the body and obtained from foods that come from animals (particularly egg yolks, meat, poultry, fish, and dairy products). The body needs this substance to build cell membranes, make certain hormones, and produce compounds that aid in fat digestion. Too much cholesterol, however, increases a person's risk of developing heart disease.

People with hypercholesterolemia have a high risk of developing a form of heart disease called coronary artery disease. This condition occurs when excess cholesterol in the bloodstream is deposited in the walls of blood vessels, particularly in the arteries that supply blood to the heart (coronary arteries). The abnormal buildup of cholesterol forms clumps (plaque) that narrow and harden artery walls. As the clumps get bigger, they can clog the arteries and restrict the flow of blood to the heart. The buildup of plaque in coronary arteries causes a form of chest pain called angina and greatly increases a person's risk of having a heart attack.

Inherited forms of hypercholesterolemia can also cause health problems related to the buildup of excess cholesterol in other tissues. If cholesterol accumulates in tendons, it causes characteristic growths called tendon xanthomas. These growths most often affect the Achilles tendons and tendons in the hands and fingers. Yellowish cholesterol deposits under the skin of the eyelids are known as xanthelasmata. Cholesterol can also accumulate at the edges of the clear, front surface of the eye (the cornea), leading to a gray-colored ring called an arcus cornealis.
Multiplicom launches MID kit for Illumina MiSeq and MASTR kits for MODY, ADH and HCM

Multiplicom launches MID kit for Illumina MiSeq and MASTR kits for MODY, ADH and HCM

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

EYLEA Injection gets approval in Japan for treatment of macular edema following CRVO

FDA issues final approval for Lupin's sNDA for Antara capsules

FDA issues final approval for Lupin's sNDA for Antara capsules

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Phase 2b study of JAK3 inhibitor VX-509 shows improvement in people with active RA

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Phase 3 ODYSSEY MONO trial with alirocumab meets primary efficacy endpoint

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

Liposorber LA-15 System to treat pediatric patients with primary FSGS gets FDA approval

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Alnylam advances Development Candidate for ALN-AS1 for treatment of hepatic porphyrias

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Amgen presents data from several romosozumab and Prolia at ASBMR 2013 Annual Meeting

Expert offers tips to help college students avoid serious health conditions down the road

Expert offers tips to help college students avoid serious health conditions down the road

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

Esperion Therapeutics reports positive results from ETC-1002 Phase 2a study for LDL-C treatment

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

European Commission approves EYLEA for treatment of visual impairment due to macular edema following CRVO

Unique computer technology opens up discovery of smarter drugs to treat illnesses

Unique computer technology opens up discovery of smarter drugs to treat illnesses

Age, sex and race may predict risk factor reduction in patients with coronary heart disease

Age, sex and race may predict risk factor reduction in patients with coronary heart disease

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

FDA grants Orphan Drug Designation to Alnylam ALN-AT3 for treatment of hemophilia B

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Regeneron, Bayer report positive results from Phase 3 VIVID-DME and VISTA-DME trials of EYLEA for DME

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Par Pharmaceutical receives final ANDA approval for generic version of Trilipix

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam releases positive top-line data from ALN-TTRsc Phase I trial for TTR-mediated amyloidosis

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Alnylam Pharmaceuticals presents new pre-clinical data of ALN-AT3 at ISTH meeting

Compared with Medicaid enrollees, low-income uninsured adults are less likely to have chronic conditions

Compared with Medicaid enrollees, low-income uninsured adults are less likely to have chronic conditions

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.